Chimeric Antigen Receptor Nk Cell Targeting Bcma
Plasma Cell Myeloma
Explore 475 assets in Plasma Cell Myeloma →Floatz Rating
C33/100
Confidence
Indicative
Sponsor
Shenzhen Pregene Biopharma Co., Ltd.
Modality
Cell therapy
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05652530CT.gov Clinical Study of the Safety and Efficacy of BCMA CAR-NK | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Plasma Cell Myeloma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Chimeric Antigen Receptor Nk Cell Targeting Bcma (this asset) | Shenzhen Pregene Biopharma Co., Ltd. | Early P1 | C · 33 |
| Vincristine Sulfate | Roswell Park Cancer Institute | P3 | BBB |
| Hyaluronidase Fihj | Massachusetts General Hospital | P4 | BBB |
| Filanesib | PETHEMA Foundation | P2 | BBB |
| Cyclosporin A | Seoul National University Hospital | P3 | BBB |
| Prednisone | GlaxoSmithKline | P4 | BB |
| Adriamycin | GlaxoSmithKline | P4 | BB |
| Cis-Diamminedichloroplatinum Ii | Janssen Research & Development, LLC | P4 | BB |
| Thalidomide | Institute of Hematology & Blood Diseases Hospital, China | P4 | BB |
+42 more in the Plasma Cell Myeloma cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Chimeric Antigen Receptor Nk Cell Targeting Bcma in Plasma Cell Myeloma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/chimeric-antigen-receptor-nk-cell-targeting-bcma-plasma-cell-myeloma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →